Tarceva (Erlotinib)
erlotinib hydrochloride
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Metastatic EGFRm NSCLC — first-line | Adults, EGFR exon 19del or L858R | Monotherapy | FDA Approved |
| Metastatic EGFRm NSCLC — maintenance | Adults, EGFR exon 19del or L858R, no progression after 4 cycles platinum-based chemo | Monotherapy | FDA Approved |
| Metastatic EGFRm NSCLC — 2nd line or beyond | Adults, EGFR exon 19del or L858R, after ≥1 prior chemo regimen | Monotherapy | FDA Approved |
| Pancreatic cancer — first-line | Adults, locally advanced/unresectable or metastatic | Combination (+ gemcitabine) | FDA Approved |
Erlotinib is a first-generation, reversible EGFR tyrosine kinase inhibitor approved for use in NSCLC and pancreatic cancer. In October 2016, the FDA restricted all NSCLC indications (first-line, maintenance, and second-line or greater) to patients whose tumors harbor EGFR exon 19 deletions or exon 21 L858R substitution mutations, based on the negative results of the IUNO trial, which showed no benefit in EGFR wild-type patients. Erlotinib is confirmed by an FDA-approved companion diagnostic before initiation. For pancreatic cancer, erlotinib is used in combination with gemcitabine regardless of EGFR mutation status, where it provided a modest but statistically significant survival benefit in the PA.3 trial. Erlotinib is not recommended in combination with platinum-based chemotherapy for NSCLC, as concurrent use showed no clinical benefit in two large randomized trials.
Although erlotinib remains FDA-approved for EGFRm NSCLC, osimertinib has largely replaced first-generation TKIs as the preferred first-line treatment based on the FLAURA trial demonstrating superior PFS and OS. Erlotinib retains a role in settings where osimertinib is unavailable or not tolerated, and for pancreatic cancer where no alternative EGFR-targeted therapy is available. NCCN guidelines list erlotinib as an option (not preferred) for first-line EGFRm NSCLC.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| EGFRm NSCLC — first-line monotherapy | 150 mg PO once daily | 150 mg PO once daily | 150 mg/day | Take on empty stomach (≥1 h before or ≥2 h after food); continue until progression or unacceptable toxicity |
| EGFRm NSCLC — maintenance after platinum-based chemo | 150 mg PO once daily | 150 mg PO once daily | 150 mg/day | Initiate in patients without progression after 4 cycles; confirm EGFR mutation status No benefit in EGFR wild-type (IUNO trial) |
| EGFRm NSCLC — 2nd/3rd line after prior chemotherapy | 150 mg PO once daily | 150 mg PO once daily | 150 mg/day | Continue until progression; no evidence that treatment beyond progression is beneficial |
| Pancreatic cancer — first-line with gemcitabine | 100 mg PO once daily | 100 mg PO once daily | 100 mg/day | With gemcitabine 1000 mg/m² IV; take erlotinib on empty stomach 150 mg cohort showed more toxicity without added benefit |
| Active cigarette smokers | 150 mg (NSCLC) or 100 mg (panc.) | Increase by 50 mg q2wk as tolerated | 300 mg/day | Advise smoking cessation; reduce immediately to standard dose upon cessation Smoking reduces erlotinib exposure by 50–64% |
| With strong CYP3A4 inducer (if unavoidable) | 150 mg (NSCLC) or 100 mg (panc.) | Increase by 50 mg q2wk as tolerated | 450 mg/day | Reduce to standard dose immediately upon stopping inducer Rifampin decreases erlotinib AUC by 58–80% |
| With strong CYP3A4 inhibitor (if unavoidable) | Reduce by 50 mg decrements | Reduced dose | Per tolerance | Avoid concurrent use if possible; ketoconazole increases erlotinib AUC by 67% |
Dose Modifications for Adverse Reactions
| Adverse Reaction | Action |
|---|---|
| ILD/Pneumonitis confirmed | Permanently discontinue erlotinib |
| Severe hepatotoxicity not resolving in 3 weeks | Discontinue erlotinib |
| Total bilirubin >3× ULN or transaminases >5× ULN (no baseline impairment) | Withhold; consider discontinuation |
| GI perforation | Permanently discontinue erlotinib |
| Severe bullous, blistering, or exfoliative skin conditions | Permanently discontinue erlotinib |
| Severe rash not responsive to medical management | Withhold; reduce by 50 mg decrements when restarting |
| Persistent severe diarrhea unresponsive to loperamide | Withhold; reduce by 50 mg decrements when restarting |
| Corneal perforation or severe ulceration | Permanently discontinue erlotinib |
| Grade ≥3 renal toxicity | Withhold; consider discontinuation |
Unlike osimertinib, erlotinib must be taken on an empty stomach because food increases bioavailability from ~60% to ~100%, creating unpredictable exposure with a narrow-therapeutic-index drug. Additionally, erlotinib solubility is pH-dependent — it dissolves best at acidic pH. Proton pump inhibitors reduce erlotinib AUC by 46%, and this interaction cannot be overcome by dose separation. PPIs should be avoided if possible. If an H2-blocker is necessary, erlotinib must be taken 10 hours after the H2-blocker dose and at least 2 hours before the next H2-blocker dose.
Pharmacology
Mechanism of Action
Erlotinib is a quinazolinamine derivative that reversibly inhibits the intracellular kinase activity of the epidermal growth factor receptor (EGFR/HER1). By blocking ATP binding at the EGFR kinase domain, erlotinib prevents autophosphorylation of tyrosine residues and suppresses downstream signaling cascades including the RAS-RAF-MEK-ERK and PI3K-AKT pathways, which drive cell proliferation, survival, and angiogenesis. Erlotinib demonstrates higher binding affinity for EGFR harboring exon 19 deletions or the exon 21 L858R substitution compared to wild-type receptor, which underpins its selective efficacy in patients with these activating mutations. Unlike third-generation TKIs such as osimertinib, erlotinib does not inhibit the T790M resistance mutation, which emerges in approximately 50% of patients during treatment and represents the most common acquired resistance mechanism.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ~60% fasted, ~100% with food; Tmax ~4 h; pH-dependent solubility (higher at lower pH) | Must take on empty stomach to avoid erratic exposure; PPIs reduce AUC by 46%; H2-blockers require 10-hour separation |
| Distribution | Vd = 232 L (apparent); protein binding 93% (albumin, alpha-1 acid glycoprotein); distributes into tumor tissue (~63% of peak plasma levels) | Extensive tissue distribution; AAG levels affect clearance; tumor penetration confirmed in surgical specimens |
| Metabolism | CYP3A4 (primary), CYP1A2, CYP1A1 (extrahepatic); active metabolite OSI-420 (<10% of parent exposure) | Highly susceptible to CYP3A4 inducers/inhibitors; smoking (CYP1A2 induction) reduces exposure by 50–64%; dual CYP vulnerability |
| Elimination | t½ 36.2 h (median); 91% recovered total: feces 83% (1% unchanged), urine 8% (0.3% unchanged); steady state 7–8 days | Primarily hepatic/biliary elimination; minimal renal excretion of intact drug; PK in renal impairment is unknown |
Side Effects
Adverse reaction data are drawn from the FDA prescribing information. NSCLC data below use Study 1 (EURTAC, first-line EGFRm NSCLC, N=84 erlotinib) and Study 4 (BR.21, 2nd/3rd-line, N=485). Pancreatic cancer data use Study 5 (PA.3, 100 mg cohort, N=259). Rash and diarrhea are the hallmark toxicities across all indications, with a pooled incidence of 70% and 42% respectively. Additional pooled adverse reactions occurring in ≥20% across all settings include anorexia, fatigue, dyspnea, cough, nausea, and vomiting (FDA PI).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Rash (grouped term) | 85% (1st-line); 75% (2nd/3rd-line) | Acneiform, maculopapular, erythematous; grade 3–4 in 8–14%; median onset 8–15 days; dose modification in 6–13% |
| Diarrhea | 62% (1st-line); 54% (2nd/3rd-line) | Grade 3–4 in 5–6%; median onset 12–32 days; loperamide first-line management |
| Anorexia / Decreased appetite | 52% (2nd/3rd-line); ≥30% (1st-line) | Grade 3–4 in 8% (Study 4); monitor weight; nutritional support if significant weight loss |
| Fatigue / Asthenia | 52% (2nd/3rd-line); ≥30% (1st-line) | Grade 3 in 14%, grade 4 in 4% (Study 4); notably, placebo arm similar (grade 3: 16%, grade 4: 4%) suggesting disease contribution |
| Cough | 48% (1st-line) | Must differentiate from ILD onset; grade 3–4 in 1% |
| Dyspnea | 45% (1st-line); 41% (2nd/3rd-line) | Often disease-related; grade 3–4 in 8–17%; evaluate ILD if new onset |
| Nausea | 33% (2nd/3rd-line) | Grade 3 in 3% (Study 4); not listed in Study 1 Table 1 (similar rate in chemotherapy arm); higher in pancreatic cancer setting |
| Infection | 24% (2nd/3rd-line) | Grade 3–4 in 4%; monitor for opportunistic infections |
| Dry skin | 21% (1st-line); 12% (2nd/3rd-line) | Emollients from treatment start; grade 3–4 in 1% |
| Back pain | 19% (1st-line) | Evaluate for disease progression vs drug effect |
| Chest pain | 18% (1st-line) | Rule out cardiac and thromboembolic causes |
| Conjunctivitis | 18% (1st-line); 12% (2nd/3rd-line) | EGFR-class effect; monitor for progression to keratitis |
| Mucosal inflammation / Stomatitis | 18% (1st-line); 17% (2nd/3rd-line) | Stomatitis and oral mucositis; grade 3–4 in <1–1% |
| Pruritus | 16% (1st-line); 13% (2nd/3rd-line) | Often accompanies rash; topical antipruritics helpful |
| Paronychia | 14% (1st-line) | EGFR-class nail toxicity; nail protection measures recommended |
| Arthralgia | 13% (1st-line) | Generally mild; grade 3–4 in 1% |
| Keratoconjunctivitis sicca | 12% (2nd/3rd-line) | Dry eye syndrome; lubricating eye drops recommended |
| Musculoskeletal pain | 11% (1st-line) | Grade 3–4 in 1% |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Alopecia | ~6% | Typically mild thinning; reversible on discontinuation |
| Epistaxis | ~3% | Usually mild; assess platelet count if recurrent |
| ALT/AST elevation (grade ≥2) | 4% ALT; 2% AST | Usually transient; may indicate hepatotoxicity; see Serious tier |
| ILD/Pneumonitis | 1.1% | Potentially fatal; median onset 39 days; see Serious tier |
| Bullous/exfoliative skin disorders | 1.2% | Includes SJS/TEN spectrum; requires immediate discontinuation |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Interstitial lung disease / Pneumonitis | 1.1% | Median 39 days (range 5 days to >9 months) | Withhold for acute pulmonary symptoms; permanently discontinue if ILD confirmed. Includes fatal cases. |
| Hepatic failure / Hepatorenal syndrome | 0.4% | Variable; higher risk with baseline hepatic impairment | Periodic LFTs; withhold if bilirubin >3× ULN or transaminases >5× ULN. Discontinue if not resolving in 3 weeks. Fatal cases reported. |
| Gastrointestinal perforation | 0.2–0.4% | Variable | Permanently discontinue erlotinib. Higher risk with concurrent anti-angiogenics, NSAIDs, corticosteroids, or taxanes. Fatal cases reported. |
| Bullous / Exfoliative skin disorders (SJS/TEN spectrum) | 1.2% | Variable | Permanently discontinue erlotinib for severe bullous, blistering, or exfoliative conditions. Fatal cases reported. |
| Renal failure | 0.5% | Variable; often related to dehydration from diarrhea | Withhold erlotinib; monitor renal function and electrolytes, especially in patients at risk of dehydration. Fatal cases reported. |
| Cerebrovascular accident (pancreatic cancer setting) | 2.5% | Variable | Reported specifically in the pancreatic cancer trial (erlotinib + gemcitabine). Includes hemorrhagic CVA. One fatal case. |
| Microangiopathic hemolytic anemia with thrombocytopenia | 1.4% (pancreatic) | Variable | Monitor CBC; evaluate for MAHA if concurrent anemia and thrombocytopenia develop. More common in pancreatic cancer setting. |
| Corneal perforation / Ulceration | Rare | Variable; ocular disorders overall in 17.8% | Discontinue for corneal perforation or severe ulceration; withhold for grade 3–4 keratitis. Ophthalmology referral. |
| Setting | Dose Modification Rate | Key Reasons |
|---|---|---|
| First-line EGFRm NSCLC (EURTAC) | 37% interrupted/reduced | Rash (13%), diarrhea (10%), asthenia (3.6%) |
| Maintenance (SATURN) | 5% reduced for rash; 3% for diarrhea | Rash, diarrhea |
| 2nd/3rd-line (BR.21) | 6% reduced for rash; 1% for diarrhea | Rash (1% discontinuation), diarrhea (1%) |
| Pancreatic cancer + gemcitabine (PA.3) | 2% reduced for rash; 2% for diarrhea | Rash, diarrhea; each ≤1% discontinuation |
Acneiform rash is the hallmark adverse effect of erlotinib, occurring in up to 85% of first-line patients with grade 3–4 severity in 14%. The rash typically appears within the first 2 weeks (median onset 8–15 days) and is concentrated on the face, upper chest, and back. Proactive management includes alcohol-free emollients, broad-spectrum sunscreen, and topical antibiotics (e.g., clindamycin 1% gel) for papulopustular eruptions. Oral doxycycline 100 mg daily may reduce severity if started prophylactically. Paradoxically, the presence and severity of rash have been correlated with improved clinical outcomes in several retrospective analyses, though this should not influence dose modification decisions.
Drug Interactions
Erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2. It has pH-dependent solubility that makes it uniquely susceptible to gastric acid-suppressing agents. Cigarette smoking (CYP1A2 induction) also substantially reduces exposure. These interactions are clinically significant and require dose adjustments or avoidance.
Monitoring
-
EGFR Mutation Status
Before initiation (NSCLC)
Routine Confirm exon 19del or L858R by FDA-approved test before all NSCLC indications. Tissue preferred; ctDNA acceptable if tissue unavailable. Not required for pancreatic cancer indication. -
Liver Function Tests
Baseline, then periodically
Routine Transaminases, bilirubin, alkaline phosphatase. Increased frequency in patients with hepatic impairment or biliary obstruction. Withhold erlotinib for bilirubin >3× ULN or transaminases >5× ULN. -
Renal Function
Baseline, then periodically
Routine Monitor creatinine and electrolytes, especially in patients at risk of dehydration from diarrhea. Withhold for grade 3–4 renal toxicity. -
INR (if on warfarin)
Regular monitoring
Routine Regularly monitor INR/PT in patients receiving concurrent warfarin or coumarin-derivative anticoagulants due to risk of elevated INR and fatal bleeding. -
Smoking Status
Each visit
Routine Active smoking reduces erlotinib exposure by 50–64%. Dose adjustments needed for smokers; immediate dose reduction upon cessation to avoid toxicity from sudden exposure increase. -
Respiratory Symptoms
Every visit
Trigger-based New or worsening dyspnea, cough, or fever should prompt ILD evaluation with HRCT. Withhold erlotinib pending results. ILD incidence is 1.1% with median onset 39 days. -
Dermatologic Assessment
Every visit
Trigger-based Assess rash severity using CTCAE grading. Evaluate for bullous, blistering, or exfoliative conditions (SJS/TEN spectrum) requiring immediate discontinuation. -
Ophthalmologic Assessment
If symptoms arise
Trigger-based Eye pain, tearing, photophobia, blurred vision, or redness require prompt ophthalmology evaluation. Ocular disorders occurred in 17.8% of NSCLC patients. Discontinue for corneal perforation.
Contraindications & Cautions
Absolute Contraindications
- The FDA prescribing information lists no formal absolute contraindications. However, the following should be treated as effective contraindications.
- Confirmed ILD during prior erlotinib treatment — permanent discontinuation is mandated; rechallenge is not recommended.
- Prior confirmed SJS/TEN on erlotinib — do not re-expose.
Relative Contraindications (Specialist Input Recommended)
- Total bilirubin >3× ULN at baseline — in a PK study of 15 patients with moderate hepatic impairment (Child-Pugh B) with significant liver tumor burden, 10 of 15 died within 30 days; 6 of the 10 had bilirubin >3× ULN at baseline (FDA PI 5.3).
- NSCLC without confirmed EGFR exon 19del or L858R — no benefit demonstrated in EGFR wild-type patients (IUNO trial).
- Concurrent use with platinum-based chemotherapy for NSCLC — no benefit and potential harm demonstrated in two large trials.
- Severe hepatic impairment (Child-Pugh C) — extreme caution required; hepatorenal syndrome risk increased.
- Active peptic ulcer disease or history of GI perforation — increased perforation risk, especially with concurrent anti-angiogenics, NSAIDs, or corticosteroids.
Use with Caution
- Concurrent PPI therapy — reduces erlotinib AUC by 46%; avoid if possible or switch to antacids with time separation.
- Current smokers — exposure reduced 50–64%; dose escalation needed but efficacy of higher doses not established long-term.
- Patients at risk of dehydration — diarrhea combined with poor oral intake can precipitate renal failure.
- Contact lens wearers — increased risk of keratitis and ocular dryness; ophthalmologic monitoring recommended.
- Concurrent warfarin — INR elevation and fatal bleeding reported; close monitoring essential.
Erlotinib can cause fetal harm. In rabbit studies, erlotinib caused embryo-fetal lethality and abortion at exposures approximately 3 times those seen at the recommended human dose of 150 mg daily. Females of reproductive potential must use effective contraception during treatment and for 1 month after the final dose. Verify pregnancy status before initiation.
Patient Counselling
Purpose of Therapy
Erlotinib is a targeted cancer therapy that blocks a protein called EGFR, which drives the growth of certain lung and pancreatic cancers. It works differently from traditional chemotherapy, targeting cancer cells more specifically. Treatment continues daily until the cancer progresses or side effects become intolerable.
How to Take
Take erlotinib on an empty stomach — at least 1 hour before eating or 2 hours after eating. This is important because food changes how much medication gets into the bloodstream. Swallow the tablet whole with water at the same time each day. Do not take erlotinib with antacids, acid-reducing medications, or grapefruit juice unless specifically instructed by the clinical team on timing.
Sources
- TARCEVA (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals, LLC; revised October 2016. FDA Label Primary source for all dosing, adverse reaction incidence rates, pharmacokinetics, warnings, and dose modification guidance.
- FDA modifies erlotinib (Tarceva) indication for NSCLC to limit use to patients with EGFR mutations. FDA News Release, October 18, 2016. FDA.gov Official FDA announcement restricting all NSCLC indications to EGFR exon 19del or L858R mutation-positive tumors based on IUNO trial results.
- Tarceva (erlotinib) [Summary of Product Characteristics]. European Medicines Agency. EMA SmPC European regulatory source with additional PK data including absolute bioavailability (59%) and tumor tissue distribution.
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC). Lancet Oncol. 2012;13(3):239-246. doi:10.1016/S1470-2045(11)70393-X EURTAC trial (Study 1): established first-line erlotinib superiority in EGFRm NSCLC with PFS HR 0.34 (10.4 vs 5.2 months).
- Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-529. doi:10.1016/S1470-2045(10)70112-1 SATURN trial (Study 3): maintenance erlotinib improved PFS (HR 0.71) and OS (HR 0.81) after first-line platinum-based chemotherapy.
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132. doi:10.1056/NEJMoa050753 BR.21 trial (Study 4): landmark study establishing erlotinib survival benefit vs placebo in 2nd/3rd-line NSCLC (OS HR 0.73).
- Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol. 2007;25(15):1960-1966. doi:10.1200/JCO.2006.07.9525 PA.3 trial (Study 5): established erlotinib + gemcitabine combination for pancreatic cancer with OS HR 0.81 (6.5 vs 6.0 months).
- Cicenas S, Geater SL, Petrov P, et al. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. 2016;102:30-37. doi:10.1016/j.lungcan.2016.10.007 IUNO trial (Study 2): demonstrated no benefit of erlotinib maintenance in EGFR wild-type NSCLC, leading to indication restriction.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 1.2025. NCCN.org Lists erlotinib as a non-preferred option for first-line EGFRm NSCLC; osimertinib is the preferred agent.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2025. NCCN.org Includes erlotinib + gemcitabine as a first-line option for locally advanced or metastatic pancreatic cancer.
- Erlotinib. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. NCBI Bookshelf Comprehensive pharmacology review covering erlotinib mechanism, ADME, adverse effects, and resistance mechanisms.
- Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006;80(2):136-145. doi:10.1016/j.clpt.2006.04.007 Population PK analysis establishing oral clearance (3.95 L/h), volume of distribution (233 L), and covariate effects including smoking on erlotinib exposure.
- Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10(7):461-466. doi:10.1634/theoncologist.10-7-461 FDA summary of the original 2004 approval for erlotinib, including the BR.21 trial data that supported the initial NSCLC indication.